Loading...
Cet enregistrement a été supprimé. Comme ce document est lié à un enregistrement publié, il est disponible ici à titre de référence uniquement.
Cliquez ici pour consulter l'enregistrement suppriméCe document a été mis à jour. Il ne s’agit pas de la dernière version publiée. Cliquez ici pour voir la dernière version du fichier.
Organisme vivant modifié
(LMO)
L’image ci-dessous identifie l’OVM par son identificateur unique, son nom commercial et un lien vers cette page du Centre d’échange Cliquer dessus pour télécharger une plus grande image sur votre ordinateur Pour du soutien sur comment utiliser, aller dans la page de liens rapides OVM.
INNOVAX® ND Vaccine
EN
HVT/NDV-F
Non
-
Personne :Dr Leonardo Bruno Ribeiro CostaPresident of Biosafety Intern Comission, CIBioAv. Sir Henry Wellcome 335, Prédio Administrativo, 1º andar, Ala "E", Moinho Velho.Cotia, São Paulo
06714-050,Téléphone : 55 (11) 4613-4000 / 4613-4006,Télécopieur : 55 (11) 4613-4000 / 4613-4006,E-mail : sonia.bognar@intervet.com,Site Web :Organisations reliéesIntervet do Brasil Veterinária Ltda (INTERVET)Secteur privé (affaires et industrie)Av. Sir Henry Wellcome 335, Prédio Administrativo, 1º andar, Ala "E", Moinho Velho.Cotia, São Paulo
06714-050,Téléphone : 55 (11) 4613-4000 / 4613-4006,Télécopieur : 55 (11) 4613-4000 / 4613-4006,E-mail : sonia.bognar@intervet.com,Site Web :
Innovax®-ND, a recombinant vaccine that helps aid in the protection of Newcastle and Marek’s diseases in chickens. Innovax-ND utilizes the herpesvirus of turkey (HVT) to carry Newcastle disease (ND) antigens, which induce immunity against ND. HVT also protects chickens against Marek’s disease, which is caused by a herpesvirus and results in tumors, high mortality and immunosuppression.
EN
Le terme « organisme récepteur » désigne un organisme (non modifié ou déjà modifié) ayant fait l'objet d'une modification génétique, tandis que les « organismes parentaux » désignent les organismes impliqués dans un croisement ou une fusion cellulaire pour générer un organisme modifié.
-
BCH-ORGA-SCBD-48969-9 Organisme Gallid alphaherpesvirus 2Virus
PB1 strain: non-virulent , non pathogenic strain of the HTV virus, which is used as a vaccine for over two decades.
EN
pNDVO4
EN
- Autres (Homologous Recombination)
Certains de ces éléments génétiques peuvent être présents sous forme de fragments ou sous forme tronquée. Veuillez consulter les notes ci-dessous, s’il y a lieu.
-
BCH-GENE-SCBD-105090-4 Fusion protein gene | Avian orthoavulavirus 1 (Newcastle disease virus, NDV)Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
The INNOVAX® ND Vaccine is a recombinant HVT strain that contains a gene that codes for the fusion protein (F-protein) of the Newcastle Disease virus, directed by promoter derived from the Rous sarcoma virus long terminal repeat sequence (LTR).
The gene was integrated into the host genome through homologous recombination as follows:
1. The protein F coding sequence was obtained through cDNA synthesis of genomic NDV, clone 30, RNA that was harvested and purified from infected embryonated eggs.
2. The F-protein coding cDNA was isolated and cloned into the HVT recombination vector pVECO4, which also contains the Rous sarcoma virus LTR promoter, resulting in the pNDVO4 plasmid.
3. pNDVO4 plasmid DNA and HVT were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
4. Selection of the recombinant virus was conducted by immunofluorescence, to detect F protein expression. The resulting strain was named HVT/NDV-F. Sequences of plasmids or markers were not detected in the recombinant virus.
EN
The gene was integrated into the host genome through homologous recombination as follows:
1. The protein F coding sequence was obtained through cDNA synthesis of genomic NDV, clone 30, RNA that was harvested and purified from infected embryonated eggs.
2. The F-protein coding cDNA was isolated and cloned into the HVT recombination vector pVECO4, which also contains the Rous sarcoma virus LTR promoter, resulting in the pNDVO4 plasmid.
3. pNDVO4 plasmid DNA and HVT were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
4. Selection of the recombinant virus was conducted by immunofluorescence, to detect F protein expression. The resulting strain was named HVT/NDV-F. Sequences of plasmids or markers were not detected in the recombinant virus.
FR
- Vaccin
FR
With the use of the Innovax ND vaccine, immunity against Newcastle Disease starts at two weeks of age and lasts for at least of 60 weeks after one single dose of the vaccine. For Marek’s Disease, immunity starts at the fifth day of age and the vaccine lastes for the whole period of risk.
The vaccine is administered to chicken embryonic eggs at 18 days of incubation through the in ovo route, or to one day chicks through subcutaneous injections.
EN
The vaccine is administered to chicken embryonic eggs at 18 days of incubation through the in ovo route, or to one day chicks through subcutaneous injections.
| Type de fichier | Champs | Fichier(s) : | |
|---|---|---|---|
| Décision de pays ou tout autre communication | Identification de l'OVM | 4 | |
| Évaluation des risques générée par un processus de réglementation | Organisme(s) vivant(s) modifié(s) | 4 | |
